Small Intestine

These ingredients are often used in alternative medicine to support small intestine.

• 1-deoxynojirimycinScientific

  1-Deoxynojirimycin (DNJ), a natural iminosugar from mulberry leaves, is a potent competitive inhibitor of small intestinal brush-border α-glucosidases (sucrase, isomaltase, glucoamylase). By blocking these enzymes it delays carbohydrate digestion and glucose absorption in the small intestine, reducing postprandial hyperglycemia. A 2024 systematic review and meta-analysis confirmed its efficacy in reducing postprandial glucose responses in humans.

• 2'-fucosyllactoseScientific

  2'-Fucosyllactose (2'-FL), the most abundant human milk oligosaccharide, exerts well-documented effects on small intestinal epithelial barrier function. It promotes intestinal cell differentiation, enhances tight junction integrity, and reduces intestinal permeability. A randomized, double-blind, placebo-controlled clinical trial (n=41) found that 3 g/day of 2'-FL significantly reduced fecal zonulin levels, indicating improved small intestinal permeability.

• acaciaScientific

  In the small intestine, acacia gum slows glucose absorption, reducing postprandial blood glucose spikes—documented in a crossover RCT (Nutrients, 2021). It also binds bile acids, reducing cholesterol reabsorption. As a non-viscous soluble fiber, it passes through the small intestine largely intact, with low viscosity preserving normal nutrient absorption.

• acemannanScientific

  Acemannan exerts mucosal healing and anti-inflammatory effects in intestinal tissue, supported by animal models of intestinal ulceration. As a prebiotic, acemannan reaches the colon after partial processing in the small intestine, where it also contributes to mucosal integrity and immune priming.

• activated charcoalScientific

  The small intestine is the primary anatomical site of activated charcoal's action. AC adsorbs toxins, drugs, and uremic precursors (such as indole) in the small intestinal lumen via surface adsorption, preventing their transport across the intestinal wall into the portal circulation. The small intestine is also the site of bile acid reabsorption that AC disrupts, and the site where toxins recirculated via enterohepatic routes are re-intercepted by AC.

• adzuki beanScientific

  Adzuki bean phenolics inhibit α-glucosidase and α-amylase in the small intestinal brush border, slowing glucose absorption. The bean's protein has direct inhibitory activity against pancreatic lipase at the small intestinal level. TCM also places Chi Xiao Dou in the Small Intestine channel for fluid and nutrient regulation.

• agarScientific

  Agar is not digested in the small intestine, as its β-glycosidic linkages resist human digestive enzymes and its agarose backbone is unaffected by intestinal pH. By forming a gel within the small intestinal lumen, agar slows the absorption of glucose and other nutrients, contributing to attenuated postprandial glucose responses and sustained satiety signaling before the fiber reaches the colon.

• ajwainScientific

  Ajwain's digestive enzyme-stimulating effects (lipase, amylase, protease) act primarily at the small intestinal level. Anti-ulcer effects in the small intestine have been documented in animal models. A human IBS clinical trial with ajwain extract showed significant improvement in intestinal discomfort.

• akkermansia muciniphilaScientific

  Akkermansia-like sequences have been detected in the human small intestine, and A. muciniphila's barrier-reinforcing effects extend to small intestinal epithelial tight junction proteins. It stimulates GLP-1 secretion from small intestinal L-cells (which are abundant in the distal small bowel), and its SCFAs influence nutrient sensing and fatty acid oxidation in the small intestinal epithelium. Permeability reduction relevant to leaky gut physiology operates across both small and large intestinal segments.

• ALA (alpha-linolenic acid)Scientific

  ALA is absorbed in the small intestine and influences local inflammatory signaling. It modulates intestinal immune responses and eicosanoid production relevant to gut health, with indirect relevance to conditions like IBD affecting the small bowel.

• alginic acidScientific

  In the small intestine, alginic acid inhibits the digestion of starch (via α-glucosidase and maltase inhibition) and fat (via pancreatic lipase inhibition), thereby reducing postprandial glucose and lipid absorption. Multiple human crossover RCTs confirm this effect for glucose; in vitro and mechanistic evidence supports lipid absorption attenuation.

• almondScientific

  In the small intestine, almonds' intact cell wall matrix limits lipid bioaccessibility, reducing fat and cholesterol absorption—a key mechanism underlying their LDL-lowering effect. Phytosterols in almonds competitively inhibit cholesterol absorption at the brush border. The cell wall's resistance to digestion also means fiber and polyphenols pass largely intact to the colon.

• aloe veraScientific

  Aloe vera has demonstrated effects on the small intestinal mucosa via its polysaccharide (acemannan) content, which exerts anti-inflammatory, mucosal-soothing, and barrier-supporting properties. Clinical evidence includes a 4-week RCT (n=79) finding aloe vera juice as effective as omeprazole and ranitidine for GERD symptom reduction, and it is included in published herbal gut-relief clinical trials showing significant GI symptom improvement. It is a traditional soothing herb documented in multiple pharmacopeias.

• amylaseScientific

  Pancreatic amylase is secreted into the duodenum where it completes the bulk of dietary starch hydrolysis. It also binds to brush-border glycoproteins in the small intestinal mucosa, exerting regulatory functions beyond digestion including modulation of glucose transport. Amylase deficiency in EPI leads to reversible villus atrophy that is restored with supplementation.

• amylopectinScientific

  The small intestine is the primary site of amylopectin digestion and glucose absorption. Pancreatic amylase released into the duodenum hydrolyzes amylopectin to oligosaccharides, which are then fully cleaved to free glucose by brush-border enzymes (sucrase-isomaltase and maltase-glucoamylase) on the enterocyte surface. Glucose is then transported across the enterocyte into the portal circulation, with hydrolysis—not absorption—being the rate-limiting step in humans.

• andrographisScientific

  Clinical and preclinical evidence places Andrographis activity in the small intestinal mucosa, particularly through its documented anti-inflammatory and mucosal healing effects in inflammatory bowel disease studies. RCT data in UC patients demonstrates mucosal healing; mechanistic studies show suppression of intestinal T-cell-driven inflammatory pathways.

• appleScientific

  In the small intestine, apple pectin slows gastric emptying and nutrient absorption, modulating postprandial glucose and lipid responses. Phloridzin, nearly exclusive to apples, inhibits SGLT-1 in the intestinal brush border, reducing glucose absorption. These effects are documented in human and mechanistic studies.

• apple cider vinegarScientific

  The small intestine is the primary site of ACV's glycemic mechanism: acetic acid inhibits disaccharidase enzymes (e.g., sucrase, maltase), slowing carbohydrate digestion and reducing the rate of glucose absorption. This is directly supported by mechanistic human studies underlying ACV's documented postprandial glucose-blunting effect.

• arabinogalactanScientific

  Arabinogalactan resists hydrolysis by small intestinal enzymes and passes through the small intestine undigested, reaching the colon intact. In vitro studies using intestinal epithelial cell models demonstrate that AG can protect intestinal barrier function and reduce inflammatory cytokines. Its transit through the small intestine without digestion is the structural basis for its prebiotic and colonic immunomodulatory actions.

• artichokeScientific

  Artichoke's key active compound cynarin stimulates bile flow from the gallbladder into the small intestine, directly affecting fat digestion and absorption. ALE also inhibits alpha-glucosidase and modulates carbohydrate digestion in the intestinal lumen. Clinical dyspepsia trials document improved digestion, reduced bloating, and normalized bowel function with ALE.

• aspergillusScientific

  By degrading gluten and other antigenic food proteins in the stomach, Aspergillus-derived enzymes (particularly AN-PEP) significantly reduce the gluten load reaching the duodenum and small intestine. Clinical trials directly measured duodenal gluten content, confirming significant reductions. A. niger-derived lactase also acts in the small intestinal brush border to hydrolyze lactose.

• atractylodesScientific

  AMR polysaccharides promote intestinal epithelial cell migration, up-regulate tight junction proteins, and modulate intestinal mucosal immunity and motility in preclinical studies. The herb has direct pharmacological effects on small intestinal function relevant to nutrient absorption and barrier integrity.

• bacillus clausiiScientific

  B. clausii spores are specifically designed to germinate in the small intestine after surviving gastric acid. In the small intestine it exerts antimicrobial effects via bacteriocins, restores mucosal flora, enhances epithelial barrier integrity, and increases mucin production. It has also been evaluated for small intestinal bacterial overgrowth (SIBO) in patients with IBS.

• bacillus coagulansScientific

  B. coagulans proliferates in the nutrient-rich small intestine environment after germinating from its spore form, where it produces digestive enzymes, metabolizes dietary sugars, competes with pathogens for adhesion sites, and produces SCFAs. Multiple clinical trials demonstrate its effects on small intestinal function including improved digestion, nutrient absorption, and reduced malabsorption symptoms.

• bananaScientific

  Green banana reduces small intestinal fluid loss and improves intestinal permeability in children with persistent diarrhea, as demonstrated in RCTs by Rabbani et al. Banana starch digestion in the small intestine is modulated by ripeness; resistant starch from green banana passes through undigested, while ripe banana starch is hydrolyzed by endogenous amylases.

• baobabScientific

  Baobab directly modulates small intestinal function: its polyphenols inhibit alpha-amylase and alpha-glucosidase enzymes in the small intestine, slowing starch hydrolysis and glucose absorption. This mechanism, demonstrated in two human RCTs, reduces the rate of glucose entry into the portal circulation. An ongoing RCT additionally designates intestinal permeability (a small intestinal barrier function marker) as its primary endpoint, with relevant biomarkers including IFABP.

• barberryScientific

  Berberine from barberry inhibits intestinal glucose absorption, exerts antimicrobial effects against small intestinal pathogens, and modulates the small intestinal microbiome. Traditional use includes treatment of small intestinal infections and diarrhea.

• barleyScientific

  In the small intestine, barley β-glucan forms a viscous gel that slows nutrient digestion and absorption, blunting postprandial glucose and insulin spikes. GBF's glutamine-rich protein fraction has been shown to support small bowel epithelial integrity.

• benegut perillaScientific

  The ex vivo antispasmodic activity of vicenin-2 — a key Benegut standardized compound — was demonstrated specifically in intestinal smooth muscle preparations, and the clinical literature identifies ileum contractions as the gut-brain stress pathway target addressed by Benegut. Intestinal barrier improvement via TEER in cell culture further implicates small intestinal epithelial function as a mechanistic site of action.

• berberineScientific

  Berberine, an isoquinoline alkaloid with millennia of use in Chinese medicine for diarrhea, exerts direct protective effects on the small intestinal mucosa. It improves intestinal barrier function by increasing goblet cells, protecting tight junction proteins, and restoring mucosal architecture. In animal models, berberine pretreatment reversed LPS-induced jejunal and ileal mucosal injury and improved glutamine transport in the small intestine.

• beta-glucanScientific

  The small intestine is the primary site of beta-glucan's metabolic and immune effects. Viscous beta-glucan gel reduces cholesterol and glucose uptake, slows gastric emptying, and stimulates GLP-1 secretion from L-cells. M cells in Peyer's patches internalize beta-glucan for systemic immune trafficking. Beta-glucan also enhances IgA expression in the small intestine.

• bifidobacterium animalisScientific

  B. animalis subsp. lactis influences the small intestinal environment through tight junction maintenance, pathogen competitive exclusion, and SCFA production. In vitro studies show BB-12 strengthens tight junctions and prevents epithelial barrier impairment. HN019 normalizes gut motility and maintains barrier function, with human clinical corroboration. Multiple strains improve macronutrient digestion and SCFA profiles in clinical studies.

• bifidobacterium bifidumScientific

  B. bifidum reinforces small intestinal epithelial tight junctions, promotes IgA production in the intestinal mucosa, and adheres to intestinal epithelial cells to modulate mucosal immunity. It has been directly shown to strengthen the intestinal TJ barrier in human cell lines and to reduce permeability caused by inflammatory cytokines. In IBS, it restores impaired mucosal immune responses documented in the small intestine.

• bifidobacterium breveScientific

  B. breve is a natural colonizer of the human intestinal tract and exerts well-documented effects on small intestinal barrier integrity, mucosal immune function, and inflammatory gene expression in neonatal and pediatric intestinal models. It improves tight junction function, reduces LPS translocation, and modulates mucosal cytokine profiles. Its colonization of intestinal microflora is detectable and quantifiable in clinical trials.

• bifidobacterium infantisScientific

  Bifidobacterium infantis is among the probiotic strains specifically studied for Crohn's disease and IBS—conditions involving small intestinal dysfunction. Strain 35624 has been shown in a large RCT to significantly reduce IBS symptom scores including abdominal pain and bloating, with mechanism involving reduction of pro-inflammatory cytokines and restoration of small intestinal immune balance.

• bifidobacterium lactisScientific

  B. lactis Bi-07 expresses β-galactosidase activity in the small intestine and has been shown in clinical trials to improve lactose digestion in lactose-maldigesting individuals. B. lactis strains also strengthen small intestinal barrier integrity by restoring tight junction proteins, reducing permeability-driven systemic inflammation.

• bifidobacterium longumScientific

  Bifidobacterium longum, including strain ES1, has documented probiotic effects on the intestinal microbiota and metabolic activity relevant to small intestinal health. A 2023 ex vivo study confirmed that B. longum ES1 supplementation beneficially modulated intestinal microbiota composition and short-chain fatty acid production. It is specifically cited among strains studied for Crohn's disease (small intestinal) and celiac disease management.

• bile saltScientific

  The small intestine is the primary site of bile salt action and reabsorption. Bile salts form mixed micelles in the duodenum and jejunum, enabling fat-soluble nutrient absorption. They are then actively reabsorbed in the terminal ileum via the apical sodium-dependent bile acid transporter (ASBT). Disruption of ileal bile salt absorption, as in Crohn's disease or ileal resection, causes bile acid malabsorption and downstream metabolic consequences.

• black pepperScientific

  The small intestine is the primary site of piperine's bioavailability-enhancing activity. Piperine stimulates brush border enzyme activity, modifies epithelial cell membrane dynamics, increases micelle formation, and inhibits P-glycoprotein efflux in the jejunal mucosa, collectively transforming nutrient and drug absorption.

• black teaScientific

  Black tea polyphenols interact with the small intestinal epithelium by inhibiting glucose transporters and digestive enzymes, modulating postprandial glycemia and lipid absorption. This mechanism supports both blood sugar and cholesterol effects observed in clinical studies. Some catechin fractions are also absorbed in the small intestine.

• boswelliaScientific

  Boswellia has been clinically trialed for Crohn's disease (affecting primarily the small intestine), with an RCT in 108 patients showing good safety for long-term use. In vitro data confirm that BSE and AKBA protect the intestinal epithelial barrier by preserving tight-junction proteins and suppressing NF-κB in enterocyte monolayers.

• bovine pancreasScientific

  Pancreatic enzymes from bovine (and porcine) pancreatin are delivered to the duodenum and small intestine, where they hydrolyze dietary fats, proteins, and carbohydrates. This is the primary site of action of PERT. Clinical trials confirm that effective delivery of pancreatin to the small intestine—preserved from gastric acid degradation via enteric coating—is essential for correcting malabsorption. The small intestinal mucosa in celiac disease also impairs activation of pancreatic enzymes via enterokinase deficiency, creating a secondary EPI.

• bromelainScientific

  Bromelain is a proteolytic enzyme complex from pineapple stem with direct enzymatic activity in the small intestine, where it aids in protein digestion and absorption. It also has anti-inflammatory properties affecting the small intestinal mucosa, and has been studied for its ability to reduce intestinal permeability and inflammation in inflammatory bowel conditions affecting the small intestine.

• brussel sproutsScientific

  Brussels sprouts interact with the small intestine as the site of glucosinolate hydrolysis and isothiocyanate absorption, vitamin C and folate absorption, and soluble fiber gel-forming activity that modulates nutrient transit and glucose absorption. I3C conversion to DIM occurs in the acidic gastric/proximal intestinal environment.

• buckthornScientific

  While the colon is the primary site of buckthorn's pharmacological action, the anthraquinone mechanism also involves increased fluid secretion into the small intestine, contributing to the overall laxative effect. This is documented in pharmacological and Commission E-derived literature. The small intestine is a secondary, not primary, site of action.

• butyrate triglycerideScientific

  Tributyrin is partially hydrolyzed to butyrate in the small intestine by pancreatic lipases, with 40–49% of the dose releasing butyrate at this location. This small intestinal butyrate release supports local epithelial energy supply and barrier function. The 2025 CoreBiome tributyrin study quantified upper GI stability and small intestinal hydrolysis rates. The small intestine is both a site of tributyrin processing and a beneficiary of released butyrate.

• butyric acidScientific

  Butyric acid (butyrate) is a short-chain fatty acid produced by colonic fermentation that serves as the preferred energy source for colonocytes and also exerts direct protective effects on small intestinal epithelial cells. It promotes intestinal barrier formation, reduces mucosal inflammation, improves wound healing, and acts as an HDAC inhibitor, stabilizing hypoxia-inducible factor (HIF) to maintain intestinal homeostasis. It is increasingly used as a direct supplement for intestinal mucosal integrity.

• campesterolScientific

  The small intestine is the primary anatomical site of campesterol's pharmacological activity. Campesterol competes with cholesterol for incorporation into intestinal micelles and interacts with NPC1L1 and ABCG5/8 transporters to limit cholesterol absorption. It is also itself partially absorbed in the small intestine, entering the bloodstream via chylomicrons.

• caprylic acidScientific

  The small intestine is the primary site of caprylic acid absorption, which occurs directly through the enterocyte brush border into the portal vein—bypassing lymphatic chylomicron transport. This unique absorption route is the basis of MCT use in malabsorptive diseases. Caprylic acid also exerts antimicrobial effects in the small intestinal lumen relevant to SIFO and potentially SIBO.

• carawayScientific

  Caraway stimulates gastric and intestinal motility, accelerating gastric emptying and small intestinal transit. A pharmacodynamic clinical study in healthy volunteers confirmed that peppermint oil and caraway oil combination accelerated gastric emptying. Caraway's spasmolytic action on small intestinal smooth muscle is well documented ex vivo.

• catechinsScientific

  Catechins are absorbed primarily in the small intestine and exert local enzyme-inhibiting effects on alpha-glucosidase, amylase, and lipase, reducing postprandial glucose and fat absorption. They also modulate incretin hormone release from small intestinal K and L cells.

• catjang cowpeaScientific

  In the small intestine, cowpea phenolics and peptides inhibit carbohydrate-digesting enzymes (α-amylase, α-glucosidase) and reduce glucose reabsorption. Cowpea also contains anti-nutritional factors partially mitigated by cooking. These effects directly modulate glycemic response.

• cellulaseScientific

  The small intestine is the primary site of cellulase activity when taken as a supplement, as it is the location of nutrient absorption and enzymatic digestion. A 2024 randomized, double-blind, placebo-controlled ileostomy study directly measured carbohydrate digestion in the small intestine using ileostomy effluent, finding that a multi-enzyme blend containing cellulase significantly increased glucose and fructose concentrations, confirming functional cellulase activity in the human small intestine.

• chamomileScientific

  Chamomile polyphenols inhibit α-glucosidase and α-amylase in the small intestine, reducing carbohydrate digestion and postprandial glucose absorption—a mechanism confirmed in vitro and corroborated by RCTs showing reduced fasting and postprandial glucose. Chamomile is also approved by the WHO monograph for treating indigestion and gastrointestinal disturbances including flatulence and diarrhea. It exerts antispasmodic effects on intestinal smooth muscle.

• chen piScientific

  Chen Pi flavonoids inhibit small intestinal α-glucosidase enzymes to slow glucose absorption, and CRP volatile oils modulate intestinal motility through smooth muscle effects. Microbiome research shows CRP reshapes the microbial ecology of the colon, with SCFA-related effects extending to intestinal health.

• chia seedScientific

  Chia mucilage forms a viscous gel in the small intestine that slows starch digestion and glucose absorption, blunts bile acid reabsorption, and reduces postprandial glycemic and lipemic responses. The simgi® gastrointestinal model study documented chia mucilage behavior specifically through small intestinal digestion phases.

• chickpea proteinScientific

  In the small intestine, chickpea resistant starch and protein slow glucose absorption by inhibiting digestive enzyme activity, significantly reducing postprandial glycaemic excursion. Chickpea protein is digested to bioactive peptides including ACE-inhibitory and DPP-IV inhibitory sequences during luminal digestion. Enteroendocrine cells in the small intestine respond to chickpea protein-derived amino acids and peptides by secreting satiety hormones.

• chicoryScientific

  Chicory inulin passes through the small intestine undigested, acting as a non-digestible dietary fiber that resists small intestinal enzymes and reaches the colon intact. In the small intestine, chicory's bitter compounds (sesquiterpene lactones) stimulate digestive secretion and motility. Clinical evidence shows chicory inulin replaces sugars with minimal small intestinal glycemic response.

• chlorophyllinScientific

  The small intestine is the primary site of aflatoxin-B1 absorption and a key site of chlorophyllin's carcinogen interception mechanism. Mouse studies of IBD and hepatic fibrosis also demonstrate that chlorophyllin reduces inflammatory markers specifically in the small intestinal tissue. Chlorophyllin's anti-inflammatory NF-κB inhibition in intestinal epithelial cells has been confirmed in vitro.

• chymotrypsinScientific

  Chymotrypsin's primary physiological site of action is the small intestine, where it is activated from chymotrypsinogen by trypsin and performs essential protein digestion. It catalyzes hydrolysis of peptide bonds adjacent to aromatic amino acids, cleaving dietary proteins into smaller peptides for absorption. This is a foundational, scientifically established physiological role.

• cinnamonScientific

  Cinnamon polyphenols inhibit intestinal α-glucosidase, maltase, and α-amylase activity, reducing carbohydrate digestion and postprandial glucose absorption. Cinnamon also modulates intestinal lipoprotein metabolism and the intestinal FXR/FGF15 signaling pathway, and demonstrates antimicrobial effects relevant to intestinal microbiota balance.

• citrus pectinScientific

  In the small intestine, citrus pectin forms a viscous gel that slows glucose and cholesterol absorption, sequesters bile acids to reduce their reabsorption, and (in modified form) is absorbed into systemic circulation. Human clinical trials confirm reduced postprandial glucose and LDL-C through these small intestinal mechanisms.

• citrus sinensisScientific

  Bioavailable C. sinensis polyphenols preferentially accumulate at the intestinal level after gastrointestinal digestion, exerting local antioxidant and anti-inflammatory effects. The Caco-2 human intestinal cell model demonstrated absorption and bioavailability of C. sinensis polyphenols. Hesperidin is hydrolyzed to hesperetin in the intestinal tract.

• cloveScientific

  Clove polyphenol extract inhibits small intestinal carbohydrate-digesting enzymes (α-amylase, α-glucosidase) in human pilot study and cell-free assays, slowing glucose absorption. Eugenol also has antispasmodic and antimicrobial relevance to small intestinal function.

• collagenScientific

  Collagen is a major structural protein of the intestinal mucosal extracellular matrix, and collagen peptides have been shown to protect tight junction proteins (ZO-1, occludin) and attenuate gut barrier dysfunction in Caco-2 cell models. A human RCT found that collagen peptide supplementation attenuated exercise-induced systemic LPS increases, suggesting partial gut barrier protection, though no significant effect on permeability markers was measured.

• colostrumScientific

  The small intestine is a primary site of action for bovine colostrum: its growth factors (EGF, IGF-1) stimulate enterocyte proliferation; immunoglobulins provide passive luminal immunity; and TGF-β regulates tight junction assembly. Human and animal data demonstrate colostrum reduces NSAID-induced small intestinal damage and improves permeability.

• commiphoraScientific

  Commiphora myrrh is used in IBD including Crohn's disease (which primarily affects the small intestine), backed by a clinical RCT with the Myrrhinil-Intest® combination. Cell studies demonstrate intestinal epithelial barrier restoration relevant to small bowel permeability.

• copperScientific

  The small intestine, particularly the proximal duodenum and jejunum, is the primary site of copper absorption. Copper transporters CTR1 and ATP7A regulate intestinal copper uptake and export to portal blood. Absorption efficiency ranges from 12–71% depending on dietary copper content, competing minerals, and other dietary factors.

• coptis chinensisScientific

  Berberine from Coptis chinensis achieves high concentrations in the small intestinal lumen after oral ingestion, exerting direct antimicrobial, anti-inflammatory, and microbiota-modulating effects. TCM uses the herb for small intestinal infections (dysentery, diarrhea) and modern evidence confirms action on intestinal bacteria and barrier function.

• cuminScientific

  Cumin significantly elevates small intestinal maltase activity in animal studies, facilitating carbohydrate digestion. Its antispasmodic and carminative properties reduce intestinal spasm and gas formation in the small bowel. The IBS trial showed cumin improved diarrhea, urgency, and bloating, symptoms partly originating in small intestinal dysfunction.

• curcuminScientific

  Curcumin, the primary bioactive of turmeric, has mechanistic and preliminary clinical evidence for supporting small intestinal health, primarily by reducing mucosal inflammation (NF-κB, COX-2 pathways), modulating intestinal tight junction proteins, and addressing IBS-related pathways. A 2026 systematic review of plant-derived IBS treatments confirmed curcumin shows mechanistic and preliminary clinical potential. Traditional Ayurvedic medicine has employed turmeric for intestinal inflammatory conditions for over 3,000 years.

• diamine oxidaseScientific

  The small intestine is the primary anatomical site of DAO production and action; DAO is synthesized by mature enterocytes of the upper intestinal villi and acts luminally to degrade dietary histamine before absorption. Small intestinal mucosal integrity is directly reflected by serum DAO levels, and any condition damaging small intestinal villi reduces DAO activity.

• docosahexaenoic acidScientific

  DHA supports small intestinal development and function, including villus height, intestinal glucose absorption, and nutrient transport protein expression. Maternal DHA supplementation during lactation significantly increases jejunal and ileal villus height in offspring. DHA modulates small intestinal microbiota and mTOR signaling relevant to intestinal growth.

• DPPIV (peptidase)Scientific

  DPPIV is naturally expressed on the brush border membrane of the small intestinal mucosa, where it participates in the terminal steps of protein digestion. As a supplement, fungal DPPIV targets the same proline-containing peptides that endogenous small intestinal DPPIV would process, with the intent of augmenting enzymatic capacity in individuals with sensitivity to gluten or casein. Brush border membrane digestion experiments have directly demonstrated the role of DPP IV in hydrolyzing immunodominant gliadin peptides.

• eicosapentaenoic acidScientific

  EPA modulates small intestinal mucosal inflammation relevant to Crohn's disease and IBD, reduces intestinal permeability via anti-inflammatory eicosanoid modulation, and Mendelian randomization data suggest EPA causally reduces IBD (including small intestinal Crohn's disease) risk.

• exopeptidaseScientific

  The small intestine is the primary site of exopeptidase action, both from brush border membrane-anchored enzymes produced by enterocytes and from pancreatic carboxypeptidases acting in the lumen. Exopeptidases in the brush border—including aminopeptidases and DPP-IV—complete terminal protein digestion adjacent to nutrient transporters. In celiac disease, small intestinal damage specifically reduces brush border exopeptidase activity, a finding supported by human clinical and biochemical evidence.

• fava beanScientific

  Fava beans interact with the small intestine as the primary site of L-DOPA, iron, folate, and protein absorption. Soluble fiber and protein in fava beans slow gastric emptying and glucose absorption in the small intestine, attenuating postprandial glycemic response. Anti-nutritional factors (phytates, tannins) can reduce mineral absorption but are substantially reduced by cooking.

• fennelScientific

  Fennel's antispasmodic and carminative effects directly target small intestinal smooth muscle, reducing gas and cramping. Clinical evidence from IBS trials captures small intestinal symptoms. Antimicrobial properties may reduce pathogenic bacterial load in the small bowel.

• fenugreekScientific

  Fenugreek directly modulates small intestinal function: its galactomannan fiber slows intestinal transit and nutrient absorption, its saponins and sapogenins inhibit sodium-dependent intestinal glucose uptake, and its polysaccharides act as prebiotics supporting intestinal microbiota. These effects are documented in in vitro, animal, and human clinical studies.

• ferula assafoetidaScientific

  Asafoetida stimulates digestive enzyme activity in the small intestine and pancreas, and its antispasmodic effect on isolated guinea pig and rat ileum (the terminal small intestine) has been confirmed experimentally. These actions directly support its use for small intestinal digestion and motility.

• flaxseedScientific

  In the small intestine, flaxseed's soluble mucilage fiber slows carbohydrate absorption, blunting postprandial glycemia. Clinical crossover trials confirm 15–30 g ground flaxseed before a meal significantly reduces the 2-hour postprandial glucose AUC in both healthy adults and type 2 diabetic patients.

• FOS (fructooligosaccharides)Scientific

  FOS passes through the small intestine largely undigested (bioavailability <5%), but improves small intestinal morphology by increasing villi height, microvilli density, and gut absorptive area. It also indirectly influences small intestinal nutrient absorption, including calcium, iron, and magnesium. In individuals with SIBO, FOS can worsen symptoms by feeding overgrown bacteria.

• fulvic acidScientific

  Fulvic acid enhances mineral absorption in the small intestine through chelation of iron, zinc, calcium, and magnesium into bioavailable complexes. It also upregulates tight junction proteins relevant to small intestinal barrier integrity and modulates mucosal immune activity.

• fungal proteaseScientific

  Fungal proteases reduce the concentration of immunogenic peptides reaching the small intestine by promoting their degradation earlier in the stomach, as demonstrated in clinical trials with AN-PEP in gluten-sensitive subjects. Fungal protease activity also supports protein digestion in the intestinal phase, enhancing amino acid absorption across the small intestinal epithelium.

• galactosidaseScientific

  The small intestine is the primary anatomical site of alpha-galactosidase enzyme action. After oral ingestion, the enzyme transits the stomach and encounters oligosaccharides in the small intestine, where it cleaves alpha-galactosidic bonds converting indigestible raffinose-family sugars into absorbable monosaccharides. This pre-colonic hydrolysis is the mechanism underlying the enzyme's efficacy in reducing downstream fermentation symptoms.

• garbanzo beanScientific

  In the small intestine, garbanzo bean components (resistant starch, soluble fiber, protein, and enzyme inhibitors) slow the digestion and absorption of carbohydrates and fats, reducing the postprandial glucose and triglyceride spikes delivered to portal circulation. This mechanism underpins their glycemic index-lowering effect documented across multiple controlled trials.

• garlic bulbScientific

  Garlic's fructans serve as prebiotic substrates in the small intestine and colon, promoting beneficial bacteria. Allicin's antimicrobial activity targets small intestinal pathogens including E. coli, Salmonella, and parasites. Traditional use for intestinal parasites and diarrhea is documented across multiple ancient cultures.

• gentianScientific

  Gentian root stimulates enzyme secretion specifically in the small intestine, as documented in Commission E pharmacology and supported by bitter receptor data. Gentiopicroside's prokinetic effects act on motilin and gastrin receptors in the duodenum, ileum, and jejunum. WHO and ESCOP monographs confirm the role of bitter principles in enhancing intestinal digestive function.

• gentian rootScientific

  The small intestine is a key site for gentian's pharmacological activity: bitter taste receptors expressed on intestinal enteroendocrine L-cells are activated by gentian secoiridoids, triggering GLP-1, CCK, and PYY secretion. An ESCOP-cited human pharmacological study confirmed gentian root increases intestinal enzyme secretion. Microencapsulated gentian secoiridoids targeted for small intestinal release showed GLP-1 stimulation in a human study. The spasmolytic effects of G. lutea on intestinal smooth muscle have also been directly studied.

• gingerScientific

  Ginger accelerates gastric emptying into the small intestine, stimulates antral contractions, and modulates small intestinal motility via muscarinic and serotonin receptor interactions. Clinical trials confirm prokinetic effects in both healthy volunteers and functional dyspepsia patients. Ginger also exerts carminative and anti-cramping effects at the intestinal level.

• glucoamylaseScientific

  Glucoamylase, as the maltase-glucoamylase (MGAM) enzyme complex, is physically embedded in the brush border membrane of the small intestinal epithelium. It catalyzes the final hydrolysis step of dietary starch to absorbable glucose. Biochemical and molecular studies in humans have extensively characterized this role.

• glucomannanScientific

  The small intestine is the primary site of glucomannan's metabolic activity. By forming a viscous gel in the intestinal lumen, glucomannan slows nutrient transit, reduces glucose and fat absorption rates, and sequesters bile acids. These actions directly modulate postprandial glucose, insulin, cholesterol, and triglyceride levels.

• glutamic acidScientific

  The small intestinal mucosa is a primary site of glutamic acid metabolism: epithelial cells express glutamate transporters and extensively oxidize dietary glutamate as an energy substrate. Glutamate receptors in the small intestinal enteric nervous system and mucosa regulate visceral sensation and secretory responses. Dietary glutamic acid influences small intestinal morphology and tight junction protein expression.

• glycineScientific

  Glycine-conjugated bile acids are released into the small intestine to facilitate fat digestion and absorption—a primary physiological role. The glycine transporter GLYT1 in small intestinal epithelial cells protects against oxidative damage. Glycine also supports mucosal collagen synthesis required for intestinal structural integrity.

• goldensealScientific

  Berberine from goldenseal has been studied in human clinical trials for small intestinal infections (cholera, bacterial diarrhea) and IBS-D, with the Merck Manual citing 'relatively well-designed studies' showing berberine reduced diarrhea from cholera and IBS. This represents scientific evidence for berberine acting in the small intestine.

• hemicellulaseScientific

  The small intestine is the primary site of action for supplemental hemicellulase, where the enzyme hydrolyzes hemicellulosic plant cell wall polymers into soluble oligosaccharides and monosaccharides. This process improves nutrient accessibility from plant foods and reduces the substrate passing unhydrolyzed to the colon. Hemicellulases used in supplements are specifically formulated to remain active across the pH range of the small intestine.

• holarrhena antidysentericaScientific

  H. antidysenterica modulates small intestinal motility via documented histaminergic and Ca²⁺ channel mechanisms (Gilani et al., 2010). Its anthelmintic activity targets intestinal worms residing in the small bowel. Alpha-glucosidase inhibition by seed extracts also occurs at the small intestinal brush border.

• honeyScientific

  Honey's antimicrobial properties protect the small intestinal mucosa from pathogenic bacteria including Salmonella, Shigella, E. coli, and H. pylori. Its anti-inflammatory polyphenols reduce intestinal mucosal inflammation, and its carbohydrates are partly absorbed in the small intestine for energy. Traditional use for GI ailments and modern evidence for H. pylori activity both involve the small intestine.

• hyacinth beanScientific

  Preclinical antidiabetic research identifies the small intestine as a key target organ for hyacinth bean's blood glucose-lowering effects, specifically via alpha-glucosidase inhibition. This enzyme, located on intestinal brush-border cells, controls the rate of carbohydrate absorption into the bloodstream.

• immunoglobin GScientific

  SBI directly targets small intestinal function by binding microbial antigens in the duodenum and small intestine, supporting mucosal CD4+ T-cell reconstitution, improving absorptive capacity, and modulating the duodenal microbiota. Human clinical studies confirm measurable benefits in duodenal immune function and D-xylose absorption.

• indian baelScientific

  Bael extracts have well-documented effects on the small intestine, including inhibition of glucose absorption, inhibition of disaccharidase and alpha-amylase enzymes, reduction of bacterial enterotoxin action at the intestinal epithelium, and protection against indomethacin-induced enterocolitis in animal models.

• indian frankincenseScientific

  Boswellia serrata acts on the small intestine through its anti-inflammatory effects on intestinal mucosa. In Crohn's disease (which primarily affects the small intestine), clinical RCTs have shown CDAI reductions. AKBA has demonstrated efficacy in experimental ileitis models. Intestinal epithelial barrier protection is documented in vitro.

• inulinScientific

  Inulin passes through the small intestine largely intact and undigested, but in doing so it modulates nutrient absorption kinetics, GLP-2-mediated intestinal integrity, and potentially reduces postprandial glucose excursions by slowing digestion. GLP-2 secreted downstream by L-cells in response to inulin fermentation maintains small intestinal mucosal integrity.

• invertaseScientific

  Invertase/sucrase acts specifically in the small intestine, anchored to the brush-border membrane of enterocytes in the duodenum and jejunum. This is the exclusive physiological site of sucrose hydrolysis and absorption in humans. Deficiency of this enzyme causes small intestinal malabsorption of sucrose with passage of intact disaccharide to the colon.

• isomalto-oligosaccharideScientific

  IMO is partially digested in the small intestine by brush border isomaltase, stimulating insulin and incretin (GLP-1) secretion from enteroendocrine L-cells. The degree of digestion depends on chain length and linkage type. Some IMO fractions also appear to repair small intestinal epithelial damage in IBS animal models.

• jujubeScientific

  Jujube polysaccharides protect small intestinal epithelial barrier function by recovering tight junctions and reducing inflammatory permeability. Jujube extracts are traditional digestive aids and have antidiarrheal and antibacterial properties relevant to small intestinal function. In vitro studies confirm intestinal epithelial barrier restoration.

• kidney beansScientific

  The small intestine is the primary site of phaseolamin-mediated alpha-amylase inhibition and resistant starch bypass. Kidney bean components slow starch hydrolysis in the small intestinal lumen, reduce glucose absorption rate, and attenuate postprandial glucose and insulin peaks. Soluble fiber delays gastric emptying and modulates small intestinal transit.

• krill oilScientific

  Krill oil modulates gut microbiota composition and enhances intestinal barrier integrity in animal models. In vitro, krill oil reduces inflammatory cytokine production in intestinal macrophages via NF-κB inhibition. A 2024 PMC review concluded krill oil has protective mechanisms relevant to intestinal inflammation and mucosal healing.

• L-alanyl-L-glutamineScientific

  The small intestine is the primary site of AG action: glutamine is the main energy substrate for enterocytes, and AG is absorbed via the PepT-1 dipeptide transporter. AG maintains small intestinal mucosal integrity, supports villous architecture, and enhances sodium-water cotransport. Clinical trials confirm AG improves small intestinal absorption and permeability in HIV/AIDS and postoperative patients.

• L-glutamineScientific

  L-Glutamine is the primary metabolic fuel for small intestinal enterocytes and is essential for maintaining mucosal cell integrity and barrier function. Meta-analyses of randomized controlled trials confirm that glutamine supplementation reduces intestinal mucosal permeability, increases intestinal villus height, and decreases inflammatory markers in surgical and critically ill patients. A 2025 retrospective clinical study also found low-dose oral glutamine improved mucosal healing in patients with external duodenal fistula.

• L-glycineScientific

  Glycine-conjugated bile salts are the dominant form of bile acids secreted into the small intestine, making glycine directly essential for fat and fat-soluble vitamin absorption. Glycine also serves as an energy substrate for enterocytes and supports intestinal mucosal integrity. Its anti-inflammatory effects may also protect the intestinal epithelium.

• L-prolineScientific

  L-Proline is absorbed in the small intestine via dedicated sodium-dependent transport systems (IMINO transporter SLC6A20 and PAT1/SLC36A1), making the small intestine a primary site of proline handling. Collagen-derived proline-rich peptides have been shown to support intestinal epithelial tight junction integrity in cell models. Collagen peptides, rich in proline, have been studied for their ability to strengthen the gut barrier and reduce intestinal permeability.

• L-threonineScientific

  L-Threonine is the primary amino acid substrate for mucin synthesis in the small intestine, particularly for MUC2, the dominant secreted mucin. Its availability directly controls goblet cell output, mucus layer integrity, villus and crypt morphology, and transepithelial permeability. This relationship is among the best-documented nutritional dependencies in intestinal physiology.

• L-tryptophanScientific

  The small intestine is the primary site of L-Tryptophan absorption and is where its most immediate physiological effects occur. Luminal tryptophan sensed by I-cells triggers CCK secretion from the duodenum and jejunum, slowing gastric emptying and stimulating digestive enzyme secretion. Enterochromaffin cells throughout the small intestine synthesize the vast majority of the body's serotonin from tryptophan.

• L-valineScientific

  L-Valine is absorbed from the small intestine via sodium-dependent active transport and is metabolized by intestinal epithelial cells (IECs) to produce glutamine, which promotes mucosal cell proliferation and intestinal morphology. Dietary valine treatment has been shown to significantly improve small intestinal villous length and villi-to-crypt ratio. L-Valine from gut microbiota protects intestinal barriers during sepsis.

• lactaseScientific

  Lactase is physiologically located on the brush border of the small intestinal mucosa, where it hydrolyzes lactose into glucose and galactose for absorption. Exogenous oral lactase supplements function within the small intestinal lumen to replicate this hydrolysis. Deficiency of small intestinal lactase, whether primary (genetic) or secondary (mucosal injury), is the direct mechanistic cause of lactose intolerance.

• lactobacillus acidophilusScientific

  Lactobacillus acidophilus colonizes both the small and large intestine and is well documented to support small intestinal mucosal health by competing with pathogenic bacteria, producing lactic acid, and supporting epithelial barrier function. Specific strain NCFM has been studied in probiotic formulas for its effects on intestinal permeability and microbiota composition. Clinical probiotic guidelines cite L. acidophilus as among the most evidence-supported strains for GI health.

• lactobacillus bulgaricusScientific

  L. bulgaricus-containing probiotic fermented milk significantly reduced small bowel permeability (lactulose/mannitol ratio from 0.038 to 0.023, p=0.004) in a randomized controlled trial in IBS-D patients. The WGO confirms L. bulgaricus improves lactose digestion (mediated by small intestinal brush-border lactase augmentation) in multiple controlled studies.

• lactobacillus caseiScientific

  Lactobacillus casei has been studied for small intestinal health in the context of Crohn's disease, IBS, and intestinal barrier function. It is specifically listed among probiotic strains with evidence in celiac disease and Crohn's disease management. Clinical trials show L. casei-containing probiotic formulas reduce intestinal permeability and inflammatory markers relevant to small intestinal mucosal integrity.

• lactobacillus gasseriScientific

  L. gasseri SBT2055 acts directly on the small intestinal immune system, inducing TGF-β expression in dendritic cells and activating TLR2 signaling to promote IgA production. It also improves glucose tolerance via modulation of small intestinal SCFA profiles and has been established in the gastrointestinal tract of humans after oral administration.

• lactobacillus paracaseiScientific

  L. paracasei modulates small intestinal physiology through reinforcement of tight junction proteins, reduction of intestinal permeability, and immunomodulation of the mucosal immune system. L. paracasei HII01 significantly reduced plasma LPS in T2DM patients in an RCT, indicating improved barrier function. NCC2461 restored gut permeability in a stress animal model.

• lactobacillus plantarumScientific

  Lactobacillus plantarum is among the most clinically studied probiotic strains for small intestinal health, directly colonizing the small intestinal mucosa and restoring epithelial permeability. Published RCTs show L. plantarum-containing formulas restore altered actin cytoskeleton and CYP1A1 expression in small intestinal epithelial cells disrupted by IBS mediators. It is consistently documented to improve IBS symptoms, including those driven by altered small intestinal function.

• lactobacillus reuteriScientific

  Lactobacillus reuteri is naturally present in the human small intestine, producing reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound active against small intestinal pathogens. RCTs show L. reuteri DSM 17938 reduces infantile colic and functional abdominal pain, and strain ATCC 55730 demonstrated benefit in Helicobacter pylori eradication adjunct therapy, relevant to the duodenal small intestinal environment.

• lactobacillus rhamnosusScientific

  Lactobacillus rhamnosus (especially strain GG) is one of the best-documented probiotics for small intestinal health. It colonizes the small intestinal mucosa, reduces intestinal permeability, modulates mucosal immune responses, and has been shown in multiple RCTs to prevent and treat traveler's diarrhea, antibiotic-associated diarrhea, and Crohn's disease-related small intestinal conditions.

• lactobacillus salivariusScientific

  L. salivarius colonizes the small intestine and has well-documented effects on small intestinal barrier function, with strain UCC118 demonstrating maintenance of tight junctions in intestinal epithelial cell lines and mucosal adhesion confirmed in human subjects. Human in vitro gut model studies and RCT microbiota data confirm its activity throughout the gastrointestinal tract including the small intestine.

• lactococcus lactisScientific

  L. lactis exerts targeted effects on the small intestine, including modulation of the intestinal GABAergic system, regulation of toll-like receptor expression in ileal mucosa, and alteration of amino acid profiles in ileal tissue. An optogenetic micro-nano delivery system was developed specifically for small intestine targeting of L. lactis to regulate vagal afferent and brain functions. Tight junction protein regulation in small intestinal epithelium has been documented.

• lactoferrinScientific

  Lactoferrin directly interacts with the small intestine via specific enterocyte receptors that mediate iron absorption, and it supports intestinal mucosal immune function and barrier integrity. Clinical evidence includes improved iron uptake, modulation of gut microbiota, and protective effects against necrotizing enterocolitis in preterm infants.

• lemon balmScientific

  Lemon balm exerts antispasmodic effects specifically on the small intestine (jejunum and ileum), confirmed in an ex vivo study on murine tissue. Site- and dose-dependent spasmolytic activity, primarily attributed to rosmarinic acid, reduces intestinal cramping. This underpins clinical efficacy in colic and functional GI complaints, approved by the German Commission E and EMA.

• lentinula edodes myceliaScientific

  Beta-glucans and polysaccharides from L. edodes mycelia interact with the gut-associated lymphoid tissue (GALT) of the small intestine as they transit through, and LEM-derived compounds modulate intestinal immune responses. Preclinical evidence shows LEM polysaccharides protect intestinal barrier integrity.

• licorice rootScientific

  Deglycyrrhizinated licorice (DGL) is well-documented for healing peptic ulcers and gastroduodenal mucosal damage, acting on the small intestinal epithelium rather than through acid suppression. Licorice flavonoid extract modulates intestinal inflammation via MAPK/NF-κB pathways in animal models. Traditional and clinical use of DGL for gastric and duodenal ulcers is authoritative-source-confirmed.

• lion's maneScientific

  Lion's Mane polysaccharides pass through the small intestine without significant degradation, preserving their prebiotic activity for colonic fermentation. In the small intestine, Lion's Mane may also inhibit alpha-glucosidase activity, slowing carbohydrate absorption and modulating blood sugar. Structural integrity of the small intestinal mucosa is supported by tight junction protein upregulation.

• lipaseScientific

  The small intestine is the primary site where pancreatic lipase acts to hydrolyze dietary triglycerides into absorbable fatty acids and monoglycerides. Lipase deficiency leads to fat malabsorption with steatorrhea, fat-soluble vitamin deficiencies, and diarrhea. PERT delivers active lipase to the duodenum to restore this function. Evidence is mechanistically established and clinically confirmed by RCTs.

• luteolinScientific

  Luteolin reduces small intestinal permeability, enriches beneficial microbial populations in the intestinal lumen, and protects the intestinal epithelial barrier from inflammatory damage in preclinical models relevant to NASH, IBD, and metabolic disease.

• magnesiumScientific

  The small intestine is the principal site of magnesium absorption, with approximately 30–50% of dietary Mg absorbed here via passive paracellular transport and active TRPM6/TRPM7 channel-mediated transcellular transport. This absorption is the primary determinant of magnesium bioavailability. PTH and vitamin D status influence intestinal Mg absorption.

• mangoScientific

  In the small intestine, mango polyphenols inhibit α-glucosidase and α-amylase enzymes, reducing carbohydrate digestion and glucose absorption rate. Mango's vitamin C is absorbed in the small intestine, as is non-heme iron whose absorption mango facilitates. Mango polyphenols may also modulate small intestinal enzyme transport systems.

• maqui berryScientific

  Maqui berry's primary mechanism of glycemic action is the inhibition of SGLT1, the sodium-glucose cotransporter located in the small intestine duodenum, which slows glucose absorption into the bloodstream. This has been demonstrated in rat duodenum and is consistent with the pharmacokinetics observed in human clinical trials.

• mastic gumScientific

  Mastic gum demonstrates H. pylori antibacterial activity relevant to the proximal small intestine/duodenum, and clinical trials confirm efficacy against duodenal ulcers. It also maintains intestinal epithelial barrier integrity by reducing paracellular permeability, demonstrated in human colon cell models and IBD patients. Masticadienonic acid upregulates tight junction proteins via the Nrf2 pathway.

• MCT (medium chain triglycerides)Scientific

  MCTs are hydrolyzed and absorbed in the small intestine via a route fundamentally different from LCTs: they do not require bile salt micellization, are not re-esterified in enterocytes, and are not incorporated into chylomicrons, instead passing directly into the portal circulation. This makes MCTs suitable for conditions with impaired small intestinal absorptive capacity, including short bowel syndrome and small intestinal lymphangiectasia.

• menthol oilScientific

  Menthol delivered to the small intestine via enteric-coated capsules relaxes intestinal smooth muscle and reduces visceral hypersensitivity, constituting the key mechanism of action in IBS treatment. Targeted delivery to the small intestine is essential for efficacy.

• millet seedScientific

  Millet seed is safe for the small intestinal mucosa in celiac disease, as it contains no gliadin-like proteins and has been confirmed non-toxic by immunochemical assays. Millet's low glycemic index and digestive enzyme-inhibiting polyphenols slow carbohydrate digestion in the small intestine, moderating glucose absorption. Its calcium bioavailability studies confirm small intestinal mineral absorption.

• mintScientific

  Peppermint oil exerts antispasmodic and antimicrobial effects in the small intestine. Enteric-coated formulations are specifically designed to release menthol in the small intestine. In vitro evidence shows PO outperforms rifaximin against E. coli, relevant to SIBO. Menthol modulates visceral sensation via TRPM8 receptors in the small intestinal wall.

• momordicaScientific

  Momordica charantia inhibits intestinal α-glucosidase and α-amylase enzymes, slowing carbohydrate digestion and absorption in the small intestine. This mechanism underpins its glycaemic activity and has been documented in vitro and in vivo. Traditional use as a digestive and laxative agent also relates to small intestinal function.

• monolaurinScientific

  Animal studies show GML supplementation in broilers improves small intestinal villus height, barrier integrity, and tight junction protein expression. Giardia lamblia (a small intestinal parasite) is reduced by 87–91% in monolaurin-treated infected animals. No human small intestine-specific interventional data exist.

• morusScientific

  The small intestine is the primary site of Morus's clinically documented mechanism: α-glucosidase inhibition by DNJ at the brush border reduces carbohydrate digestion and glucose absorption. This is confirmed in multiple human RCTs. Mulberry polyphenols also modulate intestinal microbiota and barrier function.

• mucinScientific

  The small intestinal mucosa produces mucins that lubricate the epithelium, facilitate nutrient absorption, and provide a selective barrier against pathogens and luminal antigens. MUC2 and membrane-associated mucins are expressed in the small intestine, with goblet cell density increasing toward the ileum. Mucin layer integrity in the small intestine is important for preventing bacterial translocation and maintaining immune homeostasis.

• N-acetyl-glucosamineScientific

  NAG contributes to mucosal repair in the small intestine, where it provides substrate for the glycocalyx and mucin production. Pediatric IBD studies involving small intestinal Crohn's disease showed histological improvement with NAG, and NAG's GAG-replenishing mechanism directly targets the glycoprotein-rich small intestinal epithelium.

• nut grassScientific

  C. rotundus exerts direct effects on small intestinal function: it inhibits intestinal alpha-amylase (reducing carbohydrate absorption), demonstrates antidiarrheal effects via smooth muscle relaxation, and has anthelmintic activity relevant to intestinal parasites. These are confirmed in animal and in vitro studies.

• oatScientific

  Oat β-glucan forms a viscous gel in the small intestine that slows nutrient absorption, reduces bile acid reabsorption, and attenuates postprandial glucose and insulin responses. These small intestinal effects are the primary mechanism behind oat's cholesterol-lowering and glycemic benefits.

• okraScientific

  In the small intestine, okra mucilage forms a viscous gel that slows glucose and lipid absorption, reducing postprandial glycemia and facilitating bile acid sequestration. Okra polyphenols also inhibit α-glucosidase and α-amylase in the small intestinal lumen, further blunting carbohydrate digestion. These mechanisms underpin the clinical glucose and cholesterol effects observed in RCTs.

• omega-3 fatty acidsScientific

  Omega-3 fatty acids are absorbed primarily in the small intestine and modulate intestinal immune function, barrier integrity, and inflammatory signaling. EPA and DHA influence the intestinal microbiome and reduce intestinal permeability, which has downstream effects on systemic inflammation and metabolic health.

• onionScientific

  Onion's quercetin inhibits α-glucosidase in the small intestinal brush border, slowing glucose absorption and reducing postprandial blood sugar spikes. Onion's FOS and inulin transit through the small intestine intact as dietary prebiotics. Anti-inflammatory effects of onion peel extract protect small intestinal epithelial tight junctions.

• oreganoScientific

  Oregano oil is the most-studied herbal agent for small intestinal bacterial overgrowth (SIBO), with carvacrol and thymol bactericidal against both Gram-positive and Gram-negative bacteria in the small intestinal lumen. A retrospective clinical study reported 46% SIBO eradication with herbal antimicrobials including oregano oil vs. 34% for rifaximin. A 2024 real-world clinical study incorporated oregano oil in a comprehensive SIBO regimen that achieved sustained QoL improvement.

• ox bileScientific

  The small intestine is the primary site of bile acid action: bile acids emulsify dietary fats into micelles in the duodenum and jejunum to enable lipase-mediated hydrolysis and fat-soluble vitamin absorption, then are actively reabsorbed in the terminal ileum to re-enter the enterohepatic circuit. Ox bile supplements supply exogenous bile acids to the small intestinal lumen, directly augmenting this process in states of bile deficiency.

• paederia foetidaScientific

  P. foetida modulates small intestinal motility and inhibits secretory processes relevant to diarrhea. The antidiarrheal mechanism involves inhibition of intestinal transit, and enzyme inhibition studies show α-amylase and α-glucosidase inhibitory activity in the intestinal brush border.

• palmitoleic acidScientific

  POA modulates the gut-liver axis by influencing intestinal microbiota composition and reducing gut dysbiosis-related hepatic inflammation. Preclinical evidence shows POA reduces intestinal permeability-associated signaling (LPS/TLR4 pathway) and modulates microbiota including restoration of Akkermansia.

• papainScientific

  Papain acts directly in the small intestine as a supplemental protease, breaking down dietary proteins into peptides and amino acids to enhance nutrient absorption. Clinical evidence from IBS and digestive disorder trials documents improvements in intestinal symptoms. Animal models show papain affects small intestinal propulsion, and it has been studied for supporting digestion in conditions of enzyme insufficiency.

• papayaScientific

  Papain acts primarily in the small intestinal lumen, hydrolyzing dietary proteins and aiding absorption of amino acids. It also inhibits carbohydrate and lipid-hydrolyzing enzymes in the small intestine, which may reduce postprandial glucose and triglyceride absorption. Clinical data show that papaya enzyme preparations improve digestion-related symptoms, consistent with small intestinal enzyme activity.

• peaScientific

  Intact pea protein is digested at an intermediate rate in the small intestine and specifically stimulates CCK and GLP-1 release from duodenal/jejunal enteroendocrine cells. Pea protein delays intestinal carbohydrate bioavailability, blunting postprandial glucose peaks.

• peanutScientific

  Peanut phytosterols are absorbed in the small intestine where they competitively inhibit dietary cholesterol absorption. Satiety hormones GLP-1, CCK, and PYY are secreted from small intestinal enteroendocrine cells in response to peanut fat and protein. Peanut-derived arginine is absorbed in the small intestine for systemic NO production.

• pearScientific

  In the small intestine, pear's pectin and soluble fiber slow gastric emptying and glucose absorption, blunting postprandial blood sugar and insulin responses. Chlorogenic acid specifically inhibits intestinal SGLT1 glucose transport and brush-border disaccharidases, reducing carbohydrate uptake. Pear's polyphenols are partly absorbed in the small intestine, with unabsorbed fractions passing to the colon.

• pectinScientific

  Pectin forms a viscous gel in the small intestine that slows glucose and lipid absorption, delays gastric emptying, and reduces postprandial glycemic and lipid spikes. These effects are well-documented in clinical and mechanistic research.

• PEP (prolyl endopeptidase)Scientific

  The small intestine is the primary site of damage in celiac disease and gluten sensitivity, caused by immunogenic gliadin peptides that survive gastric and pancreatic digestion and reach the intestinal mucosa intact. PEP supplementation aims to degrade these peptides in the stomach before they enter the duodenum and small intestine, thereby protecting the mucosal surface. Clinical trials confirm significant reductions in gliadin concentration in duodenal aspirates when AN-PEP is taken with gluten-containing meals.

• peppermintScientific

  Peppermint oil's primary pharmacological action in the gut is in the small intestine, where its active constituent menthol antagonizes smooth muscle calcium channels, reducing spasm and visceral hypersensitivity. Meta-analyses of RCTs and major clinical guidelines (German, Polish) recommend enteric-coated peppermint oil as a first-line treatment for IBS, including symptom relief from altered small intestinal motility and visceral pain. A 4-week RCT (n=72) showed a 40% reduction in Total IBS Symptom Score versus 24.3% for placebo.

• pepsinScientific

  Pepsin initiates gastric protein digestion by cleaving dietary proteins into smaller peptides, which are then delivered via gastric chyme into the small intestine for completion of hydrolysis and absorption. NIH StatPearls (NBK537005) characterizes pepsin as the principal enzyme of gastric protein digestion, producing peptides that are 'easily absorbed in the small intestine.' Without pepsin-initiated pre-digestion, subsequent pancreatic protease activity and small intestinal amino acid absorption are impaired. Pepsin is inactivated at the neutral pH of the intestinal lumen (pH ~7), so it acts upstream rather than within the small intestine itself.

• peptidaseScientific

  The small intestine is the primary site of action for supplemental peptidases, which are absorbed there and complete protein digestion at the brush border. Prolyl endopeptidases specifically degrade immunogenic gliadin peptides in the small intestine of celiac and gluten-sensitive individuals. Human brush border peptidases have been characterized as four distinct enzyme classes essential for completing peptide hydrolysis.

• phosphatidylcholineScientific

  PC is a critical component of bile micelles that facilitate fat and fat-soluble vitamin absorption in the small intestine. PC is also a constituent of small intestinal epithelial membranes. Gut microbial conversion of dietary PC in the small intestine generates betaine and TMAO with systemic metabolic effects.

• phytosterolsScientific

  The small intestine is the primary anatomical site of phytosterol action. Phytosterols compete with dietary and biliary cholesterol for solubilization in bile acid micelles in the small intestinal lumen, reducing cholesterol absorption by 30–50%. Key transporter proteins NPC1L1 and ABCG5/G8 in small intestinal enterocytes mediate these effects.

• pineappleScientific

  Bromelain is active in the small intestine's alkaline environment, hydrolyzing dietary proteins that human pancreatic proteases may leave incomplete. It is absorbed intact through the intestinal wall, reducing luminal inflammation and supporting mucosal integrity. IBD animal studies show anti-inflammatory effects specifically in the colon and small intestine.

• plant sterolsScientific

  The small intestine is the primary site of plant sterol action. Plant sterols competitively displace cholesterol from bile acid micelles in the intestinal lumen, reducing cholesterol absorption by competing at shared brush-border transporters (NPC1L1, ABCG5/G8). This mechanism is the foundation for all documented lipid-lowering and triglyceride effects of plant sterols in humans.

• plantagoScientific

  Psyllium (Plantago ovata) exerts its primary metabolic effects in the small intestine: forming a viscous gel that slows nutrient absorption, reduces postprandial glucose and cholesterol uptake, and binds bile acids. These small intestinal mechanisms underpin psyllium's clinical benefits for cholesterol, blood sugar, and weight management.

• plantainScientific

  Psyllium fiber's cholesterol-lowering mechanism operates in the small intestine via bile acid binding, reducing cholesterol absorption—validated in a 29-RCT meta-analysis. Mucilage polysaccharides coat small intestinal mucosa, slowing carbohydrate and fat absorption. Anti-inflammatory and antiulcerogenic compounds are relevant to small intestinal mucosa. Psyllium (P. ovata) has been specifically noted for peptic and duodenal ulcer benefit.

• pruneScientific

  In the small intestine, prune's soluble fiber (pectin) slows gastric emptying and nutrient absorption, blunting postprandial blood glucose and cholesterol uptake. Pectin also binds bile acids, increasing fecal excretion and promoting hepatic cholesterol-to-bile-acid conversion. These effects underpin prune's low glycemic index and cholesterol-lowering properties.

• psylliumScientific

  The small intestine is the primary site of psyllium's most clinically important actions. The psyllium gel increases chyme viscosity along the length of the small intestine, slowing digestion and glucose absorption. In the distal ileum specifically, the concentrated gel interferes with the active reuptake of bile acids—the mechanism responsible for psyllium's LDL-cholesterol-lowering effect. This is the mechanistic foundation for the FDA-authorized cardiovascular health claim.

• quercetinScientific

  Quercetin, a flavonoid abundant in onions, apples, and other plant foods, directly supports small intestinal tight junction integrity and reduces intestinal permeability. It has been shown in cell studies and animal models to upregulate claudin-1, ZO-1, and occludin expression in intestinal epithelial cells, reducing paracellular permeability. It is consistently used as a component in evidence-based leaky gut and intestinal barrier support formulas.

• quinoaScientific

  Quinoa is a clinically recommended gluten-free grain for celiac disease patients whose small intestinal villi are damaged by gluten exposure. Quinoa's nutritional profile addresses the malabsorption of iron, folate, and other nutrients occurring in the damaged celiac small intestine. Animal studies demonstrate quinoa protects intestinal integrity and modulates intestinal flora. Human digestibility of cooked quinoa is ~69% as assessed by simulated human digestion.

• rhubarbScientific

  Rhubarb improves small intestinal function in critically ill patients by restoring peristalsis, protecting intestinal mucosal barrier, and improving feeding tolerance. Clinical studies show rhubarb prevents bacterial translocation from the gut in severe pancreatitis. It also inhibits intestinal alpha-glucosidase activity, reducing glucose absorption.

• rhubarb rootScientific

  Rhubarb root improves small intestinal motility, barrier integrity, and mucosal immunological function, particularly in critically ill patients and SAP. Clinical and mechanistic studies document effects on intestinal permeability, mucosal barrier protection, and microbial translocation prevention.

• ryeScientific

  Rye contains secalin that causes autoimmune villous atrophy and malabsorption in the small intestine in celiac disease—a well-established, clinically critical relationship. In healthy individuals, rye's dense fiber matrix slows starch digestion and nutrient absorption in the small intestine, contributing to glycemic moderation. Most dietary fiber passes the small intestine intact to reach the colon.

• saccharomyces boulardiiScientific

  Saccharomyces boulardii is a non-pathogenic yeast with well-established clinical evidence for supporting small intestinal health. It preserves intestinal mucosal barrier integrity, enhances digestive enzyme activities in the small intestine, upregulates nutrient transport, and inhibits pathogen adhesion to intestinal epithelial cells. Clinical trials show efficacy in reducing small intestinal permeability in Crohn's disease and preventing antibiotic-associated dysbiosis.

• sclerotiumScientific

  Poria cocos sclerotium polysaccharides are absorbed by intestinal epithelial cells and gut-associated lymphoid tissue in the small intestine, modulating local immune responses and reinforcing the mucosal barrier. Beta-glucan from sclerotium directly interacts with GALT cells via Dectin-1 and TLR-2 receptors.

• sennaScientific

  Sennosides are pharmacologically inactive in the small intestine—their β-glycosidic bonds prevent hydrolysis by small intestinal enzymes, and their hydrophilic glucose moieties inhibit absorption, allowing them to pass through largely intact to the colon. This intentional bypass of the small intestine is central to senna's mechanism of action and is well-characterized in peer-reviewed pharmacological literature and NIH institutional sources. Some absorption of anthraquinone metabolites in the small intestine may contribute indirectly to colonic effects via hepatic processing.

• sitostanolScientific

  The small intestine is the primary site of sitostanol's action. Sitostanol competes with cholesterol in intestinal mixed micelles and at the brush border membrane, reducing cholesterol absorption by up to ~85%. Sitostanol itself is almost entirely non-absorbable, with 77% recovered from the intestinal lumen in tracer studies. This is the foundational mechanism underlying all downstream lipid-lowering effects.

• slippery elmScientific

  Slippery elm (Ulmus rubra) inner bark contains mucilaginous polysaccharides that coat the small intestinal mucosa, providing a demulcent and protective layer. Used by Native Americans for gastrointestinal conditions, it has antioxidant and anti-inflammatory effects suggested to tighten intestinal epithelial junctions. A published clinical trial of a herbal formula including slippery elm (with curcumin, aloe vera, guar gum, pectin, peppermint oil, and glutamine) significantly improved upper and lower GI symptoms including reduction in reflux, heartburn, abdominal pain, and bloating.

• spinachScientific

  Spinach thylakoids exert their primary action in the small intestine, binding dietary fat and carbohydrates to retard digestion, delay absorption, and extend nutrient exposure to distal L-cells. This prolongs satiety signalling (GLP-1, CCK) and reduces postprandial glucose and insulin spikes.

• SPMs (specialized pro-resolving mediators)Scientific

  SPMs are produced in small intestinal mucosa and regulate intestinal immune responses, permeability, and mucosal repair. Reduced SPM levels in Crohn's disease affecting the small intestine have been documented. Maresins specifically promote intestinal stem cell-driven epithelial regeneration.

• streptococcus thermophilusScientific

  S. thermophilus exerts primary enzymatic activity in the small intestine through beta-galactosidase release, significantly improving lactose digestion. Clinical trials using intestinal permeability markers demonstrate that S. thermophilus-containing preparations improve small intestinal permeability (reduced lactulose/mannitol ratio). It also adheres to intestinal mucosa and modulates small intestinal immune responses.

• sucraseScientific

  Sucrase is physically anchored on the brush border membrane of small intestinal enterocytes, making the small intestine both the site of sucrase synthesis and function. The small intestine is where sucrose hydrolysis and subsequent monosaccharide absorption occur; sucrase deficiency directly impairs small intestinal absorptive capacity. Pathological consequences of sucrase deficiency—osmotic diarrhea, carbohydrate malabsorption—originate in the small intestinal lumen.

• sulforaphaneScientific

  Sulforaphane protects the small intestinal mucosa from NSAID-induced injury by inducing Nrf2-driven antioxidant enzymes in enterocytes. Animal studies confirm SFN mitigates indomethacin-induced small intestinal mucosal damage. SFN also modulates the small intestinal microbiome and barrier function.

• tetrahydro iso-alpha acidsScientific

  In HFD-fed mice, THIAA increased intestinal tight junction proteins ZO-1 and occludin and reduced gut permeability — changes directly localised to the small intestinal epithelial barrier. Reduced portal LPS reflected improved small intestinal barrier function. Intestinal alkaline phosphatase, a brush-border enzyme, was also normalized.

• tributyrinScientific

  Tributyrin is partially hydrolyzed to butyrate in the small intestine, directly supporting small intestinal epithelial barrier integrity, immune function, and SCFA transporter expression. Animal studies demonstrate tributyrin preserves small intestinal barrier proteins and reduces immune disruption during ethanol challenge and antibiotic treatment.

• triphalaScientific

  Triphala demonstrates enteroprotective effects on the small intestine in preclinical studies, restoring tight junction integrity, brush border membrane function, and epithelial structure after toxic injury. Laxative and motility-modifying effects involve the small intestine via muscarinic receptor activation. Polyphenols modulate small intestinal microbial ecology.

• trypsinScientific

  The small intestine is the primary site of trypsin activation and proteolytic digestion. Trypsinogen is activated to trypsin by enteropeptidase on the duodenal brush border, and trypsin then hydrolyzes dietary proteins to peptides and amino acids essential for absorption. This is fundamental, well-established gastrointestinal physiology.

• turmericScientific

  Curcumin interacts with small intestinal function through mucosal anti-inflammatory effects, intestinal barrier reinforcement (tight junction upregulation), gut microbiome modulation, and local antioxidant activity. Its pharmacokinetics favor significant small intestinal luminal concentrations. Evidence comes from IBD, IBS, leaky gut, and microbiome studies.

• vitamin AScientific

  The small intestine is the primary site of vitamin A absorption, with uptake of retinyl esters and provitamin A carotenoids occurring predominantly in the proximal intestine (duodenum and jejunum). Vitamin A also maintains small intestinal mucosal immune function and barrier integrity, with deficiency increasing mucosal pathogen susceptibility.

• vitamin B1Scientific

  The small intestine is the primary site of thiamine absorption, with active transport occurring mainly in the jejunum and ileum. Intestinal disease, drugs, and gut microbiome alterations can disrupt thiamine absorption, causing deficiency. Thiamine also directly supports intestinal motility and gut barrier function via enteric cholinergic mechanisms.

• vitamin B12Scientific

  The small intestine is the definitive site of vitamin B12 absorption via intrinsic factor-mediated endocytosis at the terminal ileum. Diseases of the small intestine — including Crohn's disease, celiac disease, and surgical resection — directly impair B12 absorption and cause deficiency. The small intestine also receives bile-excreted B12 for enterohepatic recycling.

• vitamin B2Scientific

  The proximal small intestine is the primary site of dietary riboflavin absorption, via specific riboflavin transporter proteins (RFVT1/2/3). Active carrier-mediated transport is the predominant mechanism. Riboflavin is also converted to its coenzyme forms (FMN, FAD) in small intestinal enterocytes before release into the bloodstream.

• vitamin B6Scientific

  Vitamin B6 is absorbed primarily in the jejunum of the small intestine via a carrier-mediated process. Conditions that damage the small intestinal mucosa (e.g., celiac disease, Crohn's disease) impair B6 absorption and can cause deficiency.

• vitamin B9 (folate)Scientific

  The small intestine — specifically the duodenum and jejunum — is the primary site of folate absorption. Dietary polyglutamate folates are hydrolyzed by intestinal conjugase before active transport via the proton-coupled folate transporter (PCFT). Dysfunction of this system (e.g., hereditary folate malabsorption, tropical sprue, jejunal resection) causes folate deficiency. Folate deficiency also causes megaloblastic changes in the intestinal epithelium itself.

• wheatScientific

  In the small intestine, wheat arabinoxylan and intact grain structures slow glucose and lipid absorption by increasing luminal viscosity and physically encasing starch granules. This mechanism underlies the glycemic and insulinemic benefits of whole wheat vs. refined wheat. The small intestine is also where wheat gluten proteins are cleaved and can trigger immune responses in susceptible individuals.

• whey proteinScientific

  The small intestine is the primary site of whey protein's incretin-mediated metabolic effects. Whey digestion in the small intestine triggers GLP-1 and GIP secretion from L- and K-cells, stimulating insulin release and slowing gastric emptying. Bioactive peptides released during luminal digestion also interact with intestinal epithelial cells, modulating inflammatory responses and supporting barrier integrity.

• xylanaseScientific

  Xylanase acts primarily in the upper gastrointestinal tract, including the small intestine, where it hydrolyzes soluble arabinoxylans and reduces digesta viscosity. High arabinoxylan viscosity in the small intestinal lumen impairs nutrient contact with the epithelium and slows absorption; xylanase mitigates this. Animal research demonstrates xylanase improves villus height-to-crypt depth ratio in the small intestine, expanding the absorptive surface area.

• xylooligosaccharidesScientific

  XOS enhances small intestinal barrier integrity by upregulating tight junction proteins (ZO-1, occludin, claudin-1) and improving villus morphology. Animal studies show XOS improves the villus height-to-crypt depth ratio and intestinal epithelial structure in high-fat-diet and MASLD models.

• xyloseScientific

  The small intestine is both the primary site of D-xylose absorption and the locus of its sucrase-inhibiting action. D-xylose is absorbed by the duodenum and jejunum via a sodium-dependent mechanism, and its partial absorption allows the distal small intestine to receive luminal xylose, where it stimulates GLP-1 secretion from L-cells. The D-xylose absorption test is a validated clinical measure of small intestinal mucosal absorptive capacity.

• yeastScientific

  S. boulardii protects and modulates the small intestine by stabilizing tight junctions, inactivating enterotoxins, competing with pathogens for mucosal attachment, and inducing secretory IgA. It has documented clinical evidence for reducing small intestinal inflammation in traveler's diarrhea, acute infectious diarrhea, H. pylori eradication therapy side effects, and enteral nutrition-associated diarrhea.

• zeoliteScientific

  The small intestine is the principal site where zeolite clinoptilolite adsorbs heavy metals, mycotoxins, and luminal toxins before they are absorbed. Clinical trials show zeolite prevents intestinal lead uptake and reduces heavy metal blood levels. The 2015 RCT demonstrated improved small intestinal tight-junction integrity via zonulin reduction. G-PUR® maintained brush-border health in laboratory studies.

• zincScientific

  Zinc plays a critical structural and functional role in the small intestinal epithelium, supporting tight junction protein expression, mucosal repair, and barrier integrity. The chelated form zinc L-carnosine (PepZinGI) has been specifically shown in human crossover RCTs to prevent NSAID-induced and exercise-induced increases in small intestinal permeability by stabilizing tight junctions and increasing epithelial resistance. Zinc gluconate similarly restores intestinal mucosal barrier proteins in animal models.

• agrimonyTraditional

  Agrimony exerts documented actions in the small intestine: alpha-glucosidase inhibition (relevant to intestinal glucose absorption) is confirmed in vitro, and tannin-based astringent action reduces intestinal secretion in diarrhoea. The German Commission E and ESCOP cover this indication officially.

• aniseTraditional

  Anise's carminative, antispasmodic, and flatulence-relieving actions are traditionally directed at the small intestine, where gas accumulation and motility disturbances occur. The ESCOP monograph recognizes flatulence and bloating as therapeutic indications. Carminative action of trans-anethole on intestinal smooth muscle provides mechanistic support.

• asparagusTraditional

  Asparagus traditional use includes demulcent and stomachic properties relevant to small intestinal health. The antiulcer effects documented for A. racemosus in Ayurvedic use are relevant to duodenal and small intestinal mucosa. The high folate content of asparagus supports normal small intestinal epithelial cell proliferation. No clinical RCT evidence specific to the small intestine exists.

• baikal skullcapTraditional

  TCM attributes S. baicalensis to the small intestine meridian, and its use for diarrhea, dysentery, and intestinal infections involves the small intestine. Antibacterial effects against intestinal pathogens and intestinal barrier-protective properties are pharmacologically relevant to small intestinal health.

• belleric myrobalanTraditional

  Belleric myrobalan is documented for inflammation of the small intestine in traditional texts, and its digestive enzyme inhibitory activity (α-amylase, α-glucosidase inhibition) is pharmacologically relevant to small intestinal nutrient absorption. Its antimicrobial activity against intestinal pathogens and antispasmodic properties extend to the small intestine. Traditional use for dysentery (primarily a small intestinal condition) is documented.

• black walnutTraditional

  Black walnut hull is traditionally used to address small intestinal health, particularly for parasite and fungal overgrowth affecting this segment, and for restoring intestinal balance. The tannins and juglone exert antimicrobial and antiparasitic effects relevant to the small intestine. Traditional use is extensive.

• cat's clawTraditional

  Cat's claw is used traditionally for intestinal disorders including inflammatory and infectious conditions of the gut, with the NIH LiverTox noting its use for gastrointestinal inflammatory conditions. Preclinical studies show reduction of intestinal inflammation in animal models. Traditional use for dysentery and intestinal complaints is well-documented.

• coixTraditional

  Coix seed is used in TCM to support small intestine function via spleen-tonifying and dampness-draining actions. Mechanistically, its fiber and polysaccharides slow carbohydrate absorption, and coix prolamin hydrolysates inhibit α-glucosidase at the small intestinal brush border.

• elecampaneTraditional

  Elecampane has documented traditional action on the small intestine through its anthelmintic effects against intestinal parasites, its inulin prebiotic content that reaches the intestine to promote beneficial fermentation, and its stomachic action stimulating digestive secretions. Traditional classification spans Western and TCM systems.

• green chirettaTraditional

  Green chiretta is traditionally used in both Ayurveda and TCM for conditions of the small intestine including bacterial and parasitic infections, dysentery, and intestinal inflammation. Its antimicrobial and anti-inflammatory properties are relevant to small intestinal health.

• lophatherum leafTraditional

  In TCM, Lophatherum leaf is explicitly classified as acting on the Small Intestine meridian, through which it clears heat and routes it downward into urine. Classical formulas using the herb (such as Dao Chi San) target the Heart-Small Intestine axis. This is a traditional energetic classification without direct physiological small intestine clinical evidence.

• marjoramTraditional

  Marjoram is documented as an intestinal antispasmodic in Moroccan folk medicine and is used across traditional systems for intestinal cramping and discomfort. Preclinical digestive studies support its smooth muscle relaxant and gastroprotective mechanisms.

• marshmallowTraditional

  Marshmallow root (Althaea officinalis) contains mucilage polysaccharides that swell when hydrated, providing a soothing coating to the mucous membranes of the small intestine. Traditional European herbal medicine and the British Herbal Compendium indicate its use for soothing and protecting the stomach and intestinal tract. It also has demonstrated antioxidant properties that may inhibit intestinal inflammation.

• myrobalanTraditional

  TC is described as a gastrointestinal prokinetic agent and digestive aid that supports absorption and normal intestinal secretions. Traditional medicine lists TC for malabsorption syndrome, gastroenteritis, and intestinal dysmotility. Its antibacterial activity against small intestinal pathogens provides mechanistic support.

• phellodendron amurenseTraditional

  P. amurense bark (Huang Bai) is indicated in TCM for 'damp-heat' gastroenteritis affecting the small intestine, including watery diarrhea and dysentery with a small intestinal component. Berberine inhibits intestinal secretion, kills small intestinal pathogens (Vibrio, Salmonella, Shigella), and a berberine-free P. amurense fraction demonstrated anti-cholera toxin effects relevant to small intestinal secretory diarrhea.

• shen-chuTraditional

  In TCM theory, shen-chu influences digestion in the middle and lower digestive tract, including the small intestine, through its actions on food transformation and transportation. Modern animal studies show effects on intestinal motility and intestinal microbiota, though the small intestine is not an explicit standalone target in classical or modern literature.

• slippery elm barkTraditional

  Slippery elm is used traditionally and in integrative practice for soothing the small intestinal mucosa, particularly in malabsorption, inflammatory, or irritable conditions. The mucilage's demulcent action is proposed to coat small intestinal epithelium. The multi-ingredient formula IBS clinical study included both small and large intestinal effects.

• spearmint leafTraditional

  Spearmint has documented traditional use for intestinal weakness, indigestion, and intestinal spasm, with carvone shown to inhibit smooth muscle contractions throughout the GI tract including the small intestine. Its carminative and antispasmodic actions are well-established in ethnopharmacological records.

• sweet wormwoodTraditional

  Sweet wormwood has traditional use for intestinal parasites and dysentery, with the small intestine being a primary site of parasite and microbial activity. The anti-parasitic and antimicrobial properties of artemisinin support activity in the small intestine.

• terminaliaTraditional

  T. chebula has traditional use for duodenal ulcers and small intestinal function as a stomachic, digestive aid, and mild prokinetic. Animal studies document inhibition of duodenal ulcer development and cytoprotective effects on the duodenal mucosa. Ayurvedic pharmacopoeia documents its use for digestive disorders and gastrointestinal prokinesis.